Home › Pathophysiology › Hypoglycemic Coma

Hypoglycemic Coma

Q: What are the differential diagnostic distinctions between hypoglycemic and ketoacidotic coma?

Differential diagnosis between hypoglycemic and diabetic (ketoacidotic) coma is based on clinical and laboratory findings. FeatureHypoglycemic ComaKetoacidotic ComaProdromeHungerPronounced thirst, polyuriaSkinProfuse sweating (moist)Dry skinBloodDecreased glucose levelSharp increase in glucose, ketonemiaUrineAbsence of glucose and acetoneKetonuria

Q: What is the role of hypercatecholaminemia in the pathogenesis of hypoglycemic states?

Hypercatecholaminemia plays a dual role. On one hand, it provides a protective function by stimulating glycogenolysis and braking the development of severe hypoglycemia. On the other hand, it causes clinical manifestations (cardiac arrhythmias, muscle weakness) that serve as a signal for the patient to urgently ingest dextrose.

Q: What changes in higher nervous activity precede complete loss of consciousness?

Disorders of higher nervous activity develop gradually against the background of mounting energy deficit. Patients experience progressive drowsiness, headache, speech disturbances, and confusion, ultimately leading to coma.

Q: What fatal consequences result from impaired neuronal energy supply?

In addition to loss of consciousness and seizures, critical ATP depletion causes circulatory insufficiency (central and organ-tissue types up to collapse), as well as acute respiratory failure, which can terminate in apnea.

Q: How long after the onset of diabetes mellitus do angiopathies typically develop?

As a rule, diabetic angiopathies (microangiopathy and macroangiopathy), driven by chronic metabolic disorders in organs and tissues, appear 10–15 years after the onset of the disease, though sometimes this process begins earlier.

Coma hypoglycaemicum

For medical students2 min readUpdated 2026-10-10

Hypoglycemic coma is an acute, life-threatening condition caused by a critical drop in blood glucose levels and reduced oxygen consumption by brain cells. Neuronal energy starvation triggers a cascade of severe pathological reactions leading to loss of consciousness, seizures, and profound disruptions of respiration and circulation.

Primary targetBrain neurons suffering from rapid inhibition of ATP resynthesis

Protective responseCatecholamine surge for emergency stimulation of glycogenolysis

Marker symptomsArrhythmias and muscle weakness serving as signals to ingest dextrose

Late complicationsAngiopathies developing on average 10–15 years after diabetes onset

Initial Link of Pathogenesis

The development of such a severe condition as coma hypoglycaemicum begins with a clearly defined initial link. The foundation of the pathological process is hypoglycemia itself, which occurs in mandatory combination with decreased oxygen consumption by brain neurons. Nervous tissue is critically dependent on a continuous supply of nutrients and adequate oxygenation.

When this process is disrupted, a sharp inhibition of ATP resynthesis occurs inside neurons. The reduction in energy molecule production predictably creates a pronounced energy deficit in brain cells. The organism cannot ignore such a massive threat to the central nervous system, and in response to energy shortage, emergency activation of the sympathoadrenal system takes place. This is a key moment that moves the pathogenesis to the next stage.

Dual Role of Hypercatecholaminemia

Activation of the sympathoadrenal system leads to a state of hypercatecholaminemia, which performs two fundamentally different yet equally important functions in the body.

Protective function. A massive release of catecholamines is necessary to brake the development of severe, irreversible hypoglycemia. The main mechanism of this protection is stimulation of glycogenolysis—the breakdown of glycogen stores to release free glucose.
Clinical manifestations. It is precisely due to high catecholamine levels that the patient experiences cardiac arrhythmias, pronounced muscle weakness, and a number of other characteristic symptoms. From a clinical standpoint, these signs act as a kind of "alarm system": they are subjectively perceived by the patient and prompt them to urgently ingest dextrose (glucose) to abort the attack.

Complex of Disorders in Neuronal Energy Deficiency

If protective mechanisms fail and the patient does not ingest dextrose, the consequences of disrupted neuronal energy supply become catastrophic. A severe complex of neurological and somatic disorders develops.

Changes in higher nervous activity (HNA). This process unfolds in stages: the patient develops progressive drowsiness, speech disturbances, and a severe headache. As energy starvation deepens, confusion sets in, ultimately ending in complete loss of consciousness.
Onset of seizures. Following the suppression of HNA, the pathological process engulfs motor centers.
Circulatory insufficiency. At the final stages of the coma, vital centers suffer. This leads to central and organ-tissue vascular disorders, up to the development of profound collapse.
Respiratory failure. Concurrently, an acute lack of oxygen develops, culminating in respiratory arrest—apnea.

Long-Term Metabolic Consequences: Angiopathies

When examining acute metabolic catastrophes, one must also remember the long-term consequences of metabolic disorders in diabetes mellitus (DM). The pathogenesis of these chronic complications is likewise rooted in profound metabolic disruptions across various organs and tissues.

One of the main manifestations of such disorders is diabetic angiopathy. The timeframe for their appearance is relatively predictable: vascular lesions typically manifest 10–15 years after the onset of diabetes mellitus, although in some cases they may develop significantly earlier.

In the modern classification of diabetic angiopathies, two main forms are distinguished:

Microangiopathy — damage to small blood vessels.
Macroangiopathy — involvement of large vascular trunks in the pathological process.

Mnemonic

To remember the consequences of brain energy deficit, use the "Top-to-Bottom" rule: the cortex suffers first (HNA: drowsiness, speech disturbances, confusion), followed by the subcortex (seizures), and finally the brainstem centers (collapse and apnea).

Frequently asked questions

Which hormones, aside from catecholamines, are counter-regulatory and counteract hypoglycemia?

In addition to catecholamines, counter-regulatory/hyperglycemic hormones include:

Glucagon.
Glucocorticoids, including cortisol.
Iodothyronines — thyroid hormones.
Growth hormone (GH).
Adrenocorticotropic hormone (ACTH).

For the fasting state, the release of glucagon, GH, cortisol, and adrenaline prevents blood sugar from dropping critically by triggering glycogenolysis, gluconeogenesis, and lipolysis.

At what blood glucose level do the initial clinical signs of hypoglycemia typically appear?

The specific threshold where "initial clinical signs typically appear" is not explicitly defined.

The following thresholds are indicated:

Interventions to correct hypoglycemia should be initiated at plasma glucose < 3.9 mmol/L;
Level 1: plasma glucose from 3.0 to < 3.9 mmol/L, may present with or without symptoms;
Level 2: plasma glucose < 3.0 mmol/L, clinically significant hypoglycemia requiring immediate correction;
Level 3: severe hypoglycemia defined by altered cognitive function, including loss of consciousness/coma, and the need for assistance from another person; a specific glucose threshold is not specified.

What are the differential diagnostic distinctions between hypoglycemic and ketoacidotic coma?

Differential diagnosis between hypoglycemic and diabetic (ketoacidotic) coma is based on clinical and laboratory findings.

Feature	Hypoglycemic Coma	Ketoacidotic Coma
Prodrome	Hunger	Pronounced thirst, polyuria
Skin	Profuse sweating (moist)	Dry skin
Blood	Decreased glucose level	Sharp increase in glucose, ketonemia
Urine	Absence of glucose and acetone	Ketonuria

What is the role of hypercatecholaminemia in the pathogenesis of hypoglycemic states?